LIPO: Lipella Pharmaceuticals Inc. Stock

by  •  • Comments Off on LIPO: Lipella Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6.09
Enterprise Value ($M) 3.91
Book Value ($M) 1.92
Book Value / Share 0.75
Price / Book 3.17
NCAV ($M) 1.86
NCAV / Share 0.73
Price / NCAV 3.27

Profitability (mra)
Return on Invested Capital (ROIC) -2.55
Return on Assets (ROA) -1.60
Return on Equity (ROE) -1.96

Liquidity (mrq)
Quick Ratio 3.47
Current Ratio 3.47

Balance Sheet (mrq) ($M)
Current Assets 2.62
Assets 2.67
Liabilities 0.75
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.54
Operating Income -5.08
Net Income -5.02

Cash Flow Statement (mra) ($M)
Cash From Operations -3.95
Cash from Investing 0.00
Cash from Financing 2.84

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-09 13D/A Chancellor Michael B 4.80 0.00
04-09 13D/A Kaufman Jonathan H 4.90 0.00
11-14 13G/A Huang Leaf 5.70 -87.50
11-14 13G/A Gruber Michele 3.90 -87.16

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REP
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 418 6,938 6.02
2025-04-16 59 2,823 2.09
2025-04-15 345 11,162 3.09
2025-04-14 647 4,780 13.54

(click for more detail)

Similar Companies
LEXX – Lexaria Bioscience Corp. LFVN – LifeVantage Corporation
LGVN – Longeveron Inc. LIXT – Lixte Biotechnology Holdings, Inc.
LPCN – Lipocine Inc.


Financial data and stock pages provided by
Fintel.io